semaglutide blindness risk Big headlines this past week about and due to something called NAION (nonarteritic anterior ischemic optic neuropathy). We spoke with our buddy Dr. Brugger, an ophthalmologist, all about it. Take Wegovy linked to rare “eye

Increased contact time with the sublingual tissue may help with sublingual absorption

The results of this study found that GLP-1 receptor agonists are associated with significantly reduced rates of new substance use disorders across every major addictive substance studied, including alcohol and nicotine

Injection sites are rotated with each dose to avoid irritation

The side effect comparison and dosage chart comparison can help inform your decision

Studies have shown that patients on these medications, combined with lifestyle changes, can achieve substantial weight loss, often in the range of 15% to over 20% of their total body weight, making them a powerful tool in the fight against obesity

So the question is: Is there going to be increased pressure on the starting doses of tirzepatide and semaglutide? The restrictions on compounded GLP-1 products come as concerns about existing shortages are bubbling